The positive effect of short-term nano-curcumin therapy on insulin resistance and serum levels of afamin in patients with metabolic syndrome

Document Type : Original Research Article


1 Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran

2 Student Research Committee, Hamadan University of Medical Sciences, Hamadan, ‎Iran

3 Toxicology and Pharmacology Department, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran

4 Clinical Research Development Unit of Shahid Beheshti Hospital, Hamadan University of Medical science, Hamadan, Iran


Objective: Metabolic syndrome (MS) is a cluster of cardio-metabolic risk factors. MS is known as a highly prevalent disease worldwide. According to the existing evidence, consuming curcumin has positive effects on lipids profile, glucose, and body weight. This study aimed to evaluate the effects of nano-curcumin therapy on insulin resistance and serum level of afamin in patients with MS.
Materials and Methods: Thirty MS patients (15 males and 15 females) received 80 mg/daily nano-curcumin for two months. The samples of fasting blood were collected from the participants at the beginning and 60 days after initiation of the intervention to measure biomarkers.
Results: Comparing pre- and post-treatment with nano-curcumin values revealed a significant decrease in fasting plasma glucose (FPG) (p=0.017), insulin, homeostatic model assessment of insulin resistance (HOMA-IR) (p=0.006), and afamin (p=0.047). Moreover, there was a significantly negative relationship between afamin and high-density lipoprotein cholesterol (HDL-C) (p=0.044), as well as a significantly positive relationship between afamin and systolic (SBP) (p <0.001) and diastolic (DBP) (p <0.001) blood pressures.
Conclusion: Results suggest that taking nano-curcumin for 60 days may have positive effects on afamin, FPG, insulin, and HOMA-IR in patients with MS, but would not significantly affect other metabolic profiles. More studies with larger sample sizes are required to confirm these findings.


Alberti K, Eckel RH, Grundy SM, Zimmet PZ,
Cleeman JI, Donato KA, et al. 2009.
Harmonizing the metabolic syndrome: a
joint interim statement of the international
diabetes federation task force on
epidemiology and prevention; national
heart, lung, and blood institute; American
heart association; world heart federation;
international atherosclerosis society; and
international association for the study of
obesity. Circulation, 120:1640-1645.
Almobarak AO, Jervase A, Fadl AA, Garelnabi
NI, Al Hakem S, Hussein TM, Ahmad AA,
El-den Ahmed IS, Badi S, Ahmed MH.
2020. Prevalence of diabetes and metabolic
syndrome and associated risk factors in
Sudanese individuals with gallstones: a
cross sectional survey. TGH, 5.
Azizi F, Khalili D, Aghajani H, Esteghamati A,
Hosseinpanah F, Delavari A, et al.2010.
Appropriate waist circumference cut-off
points among Iranian adults: the first report
of the Iranian National Committee of
Obesity. Arch Iran Med, 13:243.
Cornier M-A, Dabelea D, Hernandez TL,
Lindstrom RC, Steig AJ, Stob NR, et
al.2008. The metabolic syndrome. Endocr
Rev, 29:777-822.
Dieplinger H, Dieplinger B. 2015. Afamin--A
pleiotropic glycoprotein involved in various
disease states. Clin Chim Acta, 446:105-
Du Q, Hu B, An HM, Shen KP, Xu L, Deng S,
et al.2013. Synergistic anticancer effects of
curcumin and resveratrol in Hepa1-6
hepatocellular carcinoma cells. Oncol Rep,
Ganugula R, Arora M, Jaisamut P,
Wiwattanapatapee R, Jørgensen HG,
Venkatpurwar VP, et al. 2017. Nano‐
curcumin safely prevents streptozotocin‐
Nano-curcumin reduced afamin in MS patients
AJP, Vol. 11, No. 2, Mar-Apr 2021 153
induced inflammation and apoptosis in
pancreatic beta cells for effective
management of Type 1 diabetes mellitus. Br
J Pharmacol, 174:2074-2084.
Ghasemi H, Einollahi B, Kheiripour N,
Hosseini-Zijoud SR, Farhadian Nezhad
M.2019. Protective effects of curcumin on
diabetic nephropathy via attenuation of
kidney injury molecule 1 (KIM-1) and
neutrophil gelatinase-associated lipocalin
(NGAL) expression and alleviation of
oxidative stress in rats with type 1 diabetes.
Iran J Basic Med Sci, 22:376-383.
Hatamipour M, Sahebkar A, Alavizadeh SH,
Dorri M, Jaafari MR. 2019. Novel
nanomicelle formulation to enhance
bioavailability and stability of
curcuminoids. Iran J Basic Med Sci, 22:282-
Hosseinpanah F, Borzooei S, Farshadi M,
Sarvghadi F, Azizi F. 2012. Diagnostic
values of metabolic syndrome definitions
for detection of insulin resistance: Tehran
Lipid and Glucose Study (TLGS). Arch Iran
Med, 15:606-610.
Javandoost A, Afshari A, Saberi Karimian M,
Sahebkar A, Safarian Bana H, Moammeri
M, Fathi Dizaji B, Tavalaei S, A. A. Ferns
G, Pasdar A, Parizadeh SM, Ghayour
Mobarhan M. 2018. The effects of curcumin
and a modified curcumin formulation on
serum Cholesteryl Ester Transfer Protein
concentrations in patients with metabolic
syndrome: A randomized, placebocontrolled clinical trial. Avicenna J
Phytomed, 8:330-337.
Kintscher U, Law RE.2005. PPARgammamediated insulin sensitization: the
importance of fat versus muscle. Am J
Physiol Endocrinol Metab, 288: E287-291.
Kjeldsen SE, Naditch-Brule L, Perlini S, Zidek
W, Farsang C.2008. Increased prevalence of
metabolic syndrome in uncontrolled
hypertension across Europe: the Global
Cardiometabolic Risk Profile in Patients
with hypertension disease survey. J
Hypertens, 26:2064-2070.
Ko N-Y, Lo Y-TC, Huang P-C, Huang Y-C,
Chang J-L, Huang H-B. 2019. Changes in
insulin resistance mediate the associations
between phthalate exposure and metabolic
syndrome. Environ Res, 175:434-441.
Kollerits B, Lamina C, Huth C, Marques-Vidal
P, Kiechl S, Seppala I, et al.2017. Plasma
Concentrations of Afamin Are Associated
With Prevalent and Incident Type 2
Diabetes: A Pooled Analysis in More Than
20,000 Individuals. Diabetes Care, 40:1386-
Kronenberg F, Kollerits B, Kiechl S, Lamina C,
Kedenko L, Meisinger C, et al. 2014. Plasma
concentrations of afamin are associated with
the prevalence and development of
metabolic syndrome. Circ Cardiovasc
Genet, 7:822-829.
Lichenstein HS, Lyons DE, Wurfel MM,
Johnson DA, McGinley MD, Leidli JC, et al.
1994. Afamin is a new member of the
albumin, alpha-fetoprotein, and vitamin Dbinding protein gene family. J Biol Chem,
Nishiyama T, Mae T, Kishida H, Tsukagawa
M, Mimaki Y, Kuroda M, et al.2005.
Curcuminoids and sesquiterpenoids in
turmeric (Curcuma longa L.) suppress an
increase in blood glucose level in type 2
diabetic KK-Ay mice. J Agric Food Chem,
Rahimi HR, Mohammadpour AH, Dastani M,
Jafari MR, Abnous K, Mobarhan MG,
Kazemi Oskuee R. 2016. The effect of nanocurcumin on HbA1c, fasting blood glucose,
and lipid profile in diabetic subjects: a
randomized clinical trial. Avicenna J
Phytomed, 6: 567-577.
Seeber B, Morandell E, Lunger F, Wildt L,
Dieplinger H.2014. Afamin serum
concentrations are associated with insulin
resistance and metabolic syndrome in
polycystic ovary syndrome. Reprod Biol
Endocrinol, 12:88-95.
Sharangi AB, Acharya S.2018. Spices in India
and Beyond: The Origin, History, Tradition
and Culture. Indian Spices: Springer,1-11.
Wallace TM, Levy JC, Matthews DR. 2004.
Use and abuse of HOMA modeling.
Diabetes care, 27:1487-1495.
Watson KE, Horowitz BN, Matson G. 2019.
Lipid abnormalities in insulin resistant
states. RCM. 25:228-36
Xu X-Y, Meng X, Li S, Gan R-Y, Li Y, Li HB.2018. Bioactivity, Health Benefits, and
Related Molecular Mechanisms of
Curcumin: Current Progress, Challen